Over the last two years, dozens of telehealth companies have started to offer the wildly popular GLP-1 drugs. A new STAT examination has found that just a handful of networks of doctors, nurse practitioners, and physician assistants are writing prescriptions for the slew of websites offering the weight loss drugs, including the compounded versions that...
Tag: <span>GLP-1</span>
Post
Study shows bariatric surgery outperforms GLP-1 diabetes drugs for kidney protection
September 20, 2024 by Cleveland Clinic Credit: Pixabay/CC0 Public DomainA Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic kidney disease compared to those who received GLP-1 diabetes medications. The paper was published in Annals...
Post
Keeping your good mood while taking GLP-1s could take some intentionality, experts say
By Madeline Holcombe, CNN Updated 6:08 PM EDT, Thu September 19, 2024 Research has not shown a definitive connection between GLP-1s and mental health concerns. Jens Kalaene/picture alliance/Getty ImagesEditor’s note: If you or someone you know is struggling with suicidal thoughts or mental health matters, please call the 988 Suicide & Crisis Lifeline by dialing...
Post
GLP-1 pills are coming, and they could revolutionize weight-loss treatment
By Meg Tirrell, CNNPublished 6:30 AM EDT, Tue September 17, 2024 The new crop of GLP-1 weight loss drugs all come in the form of injections. New pill versions are in trials now. Illustration by Leah Abucayan/CNNJared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually...
Post
Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution
Medscape Medical News Megan Brooks August 20, 2024 A new analysis has detected a signal of suicidal ideation associated with the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide, especially among individuals concurrently using antidepressants or benzodiazepines. However, the investigators and outside experts urge caution in drawing any firm conclusions based on the study’s observations....
Post
Thyroid Warning on GLP-1s Could Raise Overdiagnosis Risk
Medscape Medical News > Conference News Kerry Dooley Young July 02, 2024 ORLANDO, Florida — Clinicians should keep in mind concerns about overdiagnosis of thyroid cancer when prescribing glucagon-like peptide 1 (GLP-1) drugs, as the US black box warning about this risk for this class of medicines for certain tumors in mice could trigger excess...
Post
Mounjaro, Zepbound: What Happens to Your Body When You Stop Taking Weight Loss Drugs
Mounjaro and Zepbound can help qualified individuals lose and maintain weight and blood glucose levels. These medicines are not recommended for short-term use. Stopping them can prompt weight regain, blood sugar spikes, and increased appetite, among other side effects. Like Ozempic and Wegovy, Mounjaro and Zepbound can help people control blood sugar levels and reduce...
Post
Losing Muscle with GLP-1 RAs? There May be a Drug for That
NEW ORLEANS — Medications in development would preserve muscle mass and augment fat loss when used in combination with glucagon-like peptide 1 (GLP-1) receptor agonists taken for weight loss. As drugs such as semaglutide (Wegovy) and the dual agonist glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Zepbound) are producing unprecedented degrees of weight loss in increasing numbers...
Post
GI Complications With GLP-1s for Weight Loss: Reexamining the Risks
Medscape Medical News > Conference News > DDW 2024 Damian McNamara, MA May 23, 2024 WASHINGTON, DC — In contrast with a previous study that found glucagon-like peptide 1 (GLP-1) receptor agonists associated with an increased risk for acute pancreatitis and bowel obstruction, a new retrospective study found no significant link to these complications. The...
Post
‘Obesity plus’: What’s next for GLP-1s?
Ayisha SharmaNews ReporterKatherine LewinNews ReporterNovo Nordisk and Eli Lilly are set to make billions of dollars each year off their GLP-1s, but patients and prescribers are still eager for improved drugs, citing GI side effects, muscle loss and weight gain after stopping treatment Add in the potential for drugs like Novo’s semaglutide (marketed as Wegovy...